Clinical Trials Browser

Completed × Recurrent Squamous Cell Lung Carcinoma × tremelimumab × Clear all

NCT03373760 2023-06-09

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Phase 2 Completed

67 enrolled 17 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma